

Corium International Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 26-Apr-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 10

 Phase 1 Clinical..... 11

 Discovery..... 13

 Suspended..... 28

[Return to Table of Contents](#)

Corium International Inc

COMPANY OVERVIEW

| | |
|---------------------------------------|--|
| Company Name | Corium International Inc |
| Parent Company Name | Corium International Inc |
| Website | http://www.coriumgroup.com/ |
| Country | US |
| Number of Drugs in Active Development | 7 |
| Number of Inactive Drugs | 0 |
| Number of Patents as Owner | 5 |
| Number of Patents as Third Party | 0 |
| Number of Deals | 4 |
| Key Indications | Alzheimers disease,Osteoporosis,Prostate hyperplasia,Parkinsons disease,Poliovirus infection,Psychiatric disorder,Acne,Aging,Hyperpigmentation,Urinary dysfunction,Urinary tract |
| Key Target-based Actions | Acetylcholinesterase inhibitor,Parathyroid hormone receptor agonist,Alpha adrenoceptor antagonist,Dopamine D2 receptor agonist,Dopamine D3 receptor agonist,NMDA receptor antagonist,Parathyroid hormone ligand,Alpha 1A adrenoceptor antagonist |
| Key Technologies | Transdermal formulation,Patch formulation,Small molecule therapeutic,Biological therapeutic,Drug combination,Peptide,Controlled release formulation,Absorption enhancer transdermal,Formulation preservation,Sustained release formulation |

COMPANY PROFILE

SUMMARY

Corium International Inc specializes in the R&D and manufacture of transdermal drug delivery platforms and products.

FINANCIAL

In December 2014, the company revised and closed an expanded term loan facility with CRG (previously known as Capital Royalty L.P.). Under the revised term, the company would get additional \$10 million from CRG cumulating the total loan amount to \$45 million and the maturity date of the all the debt to CRG was changed from June 2017 to June 2019.

In March 2014, Corium filed a registration statement Form S-1 with the US SEC for a proposed initial public offering of common stock. At that time, the company planned to list on the NASDAQ Global Market under the ticker symbol 'CORI'. In April 2014, the company priced its initial public offering of 6,500,000 shares of common stock priced at \$8.00 each and the underwriters were granted a 30-day option to purchase up to 975,000 additional shares of common stock. At that time, the shares began trading on the NASDAQ Stock Market. By May 2014, the initial public offering was completed and the company raised \$48.5 million net proceeds through the offering.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

| Indication | Active | Inactive | Total |
|-------------------------|--------|----------|-------|
| Neurological disease | 4 | 0 | 4 |
| Degeneration | 3 | 0 | 3 |
| Andrology | 1 | 0 | 1 |
| Inflammatory disease | 1 | 0 | 1 |
| Genitourinary disease | 1 | 0 | 1 |
| Endocrine disease | 1 | 0 | 1 |
| Psychiatric disorder | 1 | 0 | 1 |
| Musculoskeletal disease | 1 | 0 | 1 |
| Growth disorder | 1 | 0 | 1 |
| Infectious disease | 1 | 0 | 1 |

Drugs by Highest Status

Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

Drugs by Highest Status Table

| Development Status | Number of Drugs |
|--------------------|-----------------|
| Phase 1 Clinical | 1 |
| Discovery | 5 |
| Suspended | 1 |

DEALS

| Deal Type | Principal | | Partner | | Total |
|--|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Drug - Funding | 1 | 0 | 0 | 0 | 1 |
| Drug - Development/Commercialization License | 0 | 0 | 1 | 0 | 1 |
| Drug - Manufacturing/Supply | 2 | 0 | 0 | 0 | 2 |

CLINICAL TRIALS

Trials by Phase

| Phase | Ongoing | All |
|---------|---------|-----|
| Phase 2 | 0 | 1 |
| Phase 1 | 0 | 1 |

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

| Indication | As Owner | As Third Party | Total |
|--------------------------|----------|----------------|-------|
| Cardiovascular disease | 1 | 0 | 1 |
| Endocrine disease | 6 | 0 | 6 |
| Gastrointestinal disease | 2 | 0 | 2 |
| Genitourinary disease | 1 | 0 | 1 |
| Growth disorder | 1 | 0 | 1 |

[Return to Table of Contents](#)



| | | | |
|-------------------------|---|---|---|
| Degeneration | 6 | 0 | 6 |
| Andrology | 1 | 0 | 1 |
| Psychiatric disorder | 1 | 0 | 1 |
| Musculoskeletal disease | 5 | 0 | 5 |
| Neoplasm | 1 | 0 | 1 |
| Metabolic disorder | 1 | 0 | 1 |
| Neurological disease | 3 | 0 | 3 |
| Respiratory disease | 1 | 0 | 1 |
| Infectious disease | 3 | 0 | 3 |
| Injury | 1 | 0 | 1 |
| Inflammatory disease | 2 | 0 | 2 |
| Dermatological disease | 1 | 0 | 1 |
| Ulcer | 1 | 0 | 1 |

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

teriparatide (transdermal, MicroCor, osteoporosis), Corium International

teriparatide (transdermal, MicroCor, osteoporosis), Corium International SNAPSHOT

| | |
|-----------------------------|--|
| Drug Name | teriparatide (transdermal, MicroCor, osteoporosis), Corium International |
| Key Synonyms | teriparatide;MicroCor PTH(1-34) |
| Originator Company | Corium International Inc |
| Active Companies | Corium International Inc |
| Inactive Companies | |
| Highest Status | Phase 1 Clinical |
| Active Indications | Osteoporosis |
| Target-based Actions | Parathyroid hormone ligand;Parathyroid hormone receptor agonist |
| Other Actions | Osteoblast stimulator;Bone synthesis stimulator |
| Technologies | Patch formulation;Biological therapeutic;Transdermal formulation;Peptide |
| Last Change Date | 17-Feb-2015 |

teriparatide (transdermal, MicroCor, osteoporosis), Corium International DEVELOPMENT PROFILE

SUMMARY

Corium International is developing transdermal patch formulation of teriparatide (human PTH(1-34); MicroCor PTH(1-34)) using its MicroCor technology, for the potential treatment of osteoporosis. In June 2011, the drug was listed as being in phase II development. However, in November 2013, the drug was listed as being in phase I development. In May 2014, phase II trials for osteoporosis were planned for 2015. By September 2014, the company had been planning to initiate a phase IIa study which was expected to complete in the first half of 2015 followed by a phase IIb study in osteoporosis patients and a phase III trial. At that time, the company was seeking to outlicense the drug for commercialization.

teriparatide (transdermal, MicroCor, osteoporosis), Corium International DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

| Company | Indication | Country | Development Status | Date |
|--------------------------|--------------|---------|--------------------|-------------|
| Corium International Inc | Osteoporosis | US | Phase 1 Clinical | 06-Nov-2013 |

[Return to Table of Contents](#)

teriparatide (transdermal, MicroCor, osteoporosis), Corium International DRUG NAMES

| Names | | Type |
|--|--|------------|
| teriparatide (transdermal, MicroCor, osteoporosis), Corium International | | |
| teriparatide | | INN, USAN |
| PTH (1-34) (transdermal, MicroCor, osteoporosis), Corium International | | |
| MicroCor PTH(1-34) | | Trade Name |

teriparatide (transdermal, MicroCor, osteoporosis), Corium International CLINICAL TRIALS


Total Trials by Phase and Status

| Phase 4 Clinical | | Phase 3 Clinical | | Phase 2 Clinical | | Phase 1 Clinical | | Phase Unspecified | | Total | |
|---------------------------|-----|------------------|-----|------------------|-----|------------------|-----|-------------------|-----|----------|-----|
| On-going | All | On-going | All | On-going | All | On-going | All | On-going | All | On-going | All |
| Total by Phase and Status | | | | | | | | | | | |
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |

teriparatide (transdermal, MicroCor, osteoporosis), Corium International DEALS AND PATENTS

PATENTS

Patents by Parent Company Chart




[Return to Table of Contents](#)

Patents by Parent Company Table

| Company Name | As Owner | As Third Party | Total |
|--------------------------|----------|----------------|-------|
| Corium International Inc | 4 | 0 | 4 |

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

| Drug Relationship | Total |
|-------------------|-------|
| Delivery device | 4 |

donepezil + memantine (transdermal patch, Alzheimers disease), Corium

donepezil + memantine (transdermal patch, Alzheimers disease), Corium SNAPSHOT

| | |
|----------------------|---|
| Drug Name | donepezil + memantine (transdermal patch, Alzheimers disease), Corium |
| Key Synonyms | |
| Originator Company | Corium International Inc |
| Active Companies | Corium International Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Alzheimers disease |
| Target-based Actions | Acetylcholinesterase inhibitor;NMDA receptor antagonist |
| Other Actions | Nootropic agent;Neuroprotectant |
| Technologies | Patch formulation;Small molecule therapeutic;Drug combination;Transdermal formulation |
| Last Change Date | 17-Feb-2015 |

donepezil + memantine (transdermal patch, Alzheimers disease), Corium DEVELOPMENT PROFILE

SUMMARY

Corium International is investigating a combination of donepezil, an acetylcholinesterase inhibitor, and memantine, an NMDA receptor antagonist, as a transdermal patch formulation, for the potential treatment of Alzheimer's disease. In September 2014, the combination was in preclinical development and at that time, the company was expecting to develop the combination under a 505(b)(2) regulatory pathway.

donepezil + memantine (transdermal patch, Alzheimers disease), Corium DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS


| Company | Indication | Country | Development Status | Date |
|--------------------------|--------------------|---------|--------------------|-------------|
| Corium International Inc | Alzheimers disease | US | Discovery | 30-Sep-2014 |


donepezil + memantine (transdermal patch, Alzheimers disease), Corium CHEMICAL STRUCTURES

[Return to Table of Contents](#)



| | |
|--|-------------------|
| CAS Registry Number: | Confidence Level: |
| | 1 |
|  | |
| Name | Type |
| donepezil + memantine | |

| | |
|---|-------------------|
| CAS Registry Number: | Confidence Level: |
| 120014-06-4 | 1 |
|  | |
| Name | Type |
| donepezil | BAN; INN |
| NAL-8812 | Research Code |
| NAL-8817 | Research Code |

| | |
|---|-------------------|
| CAS Registry Number: | Confidence Level: |
| 19982-08-2 | 1 |
|  | |

[Return to Table of Contents](#)

| Name | Type |
|--------------|---------------|
| memantine | BANN; INN |
| D-145 | Research Code |
| memantine ER | |

donepezil + memantine (transdermal patch, Alzheimers disease), Corium DRUG NAMES

| Names | Type |
|---|------|
| donepezil + memantine | |
| donepezil + memantine (transdermal patch, Alzheimers disease), Corium | |

[Return to Table of Contents](#)

donepezil (transdermal patch, Alzheimers disease), Corium

donepezil (transdermal patch, Alzheimers disease), Corium SNAPSHOT

| | |
|----------------------|--|
| Drug Name | donepezil (transdermal patch, Alzheimers disease), Corium |
| Key Synonyms | |
| Originator Company | Corium International Inc |
| Active Companies | Corium International Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Alzheimers disease |
| Target-based Actions | Acetylcholinesterase inhibitor |
| Other Actions | Neuroprotectant;Nootropic agent |
| Technologies | Patch formulation;Small molecule therapeutic;Transdermal formulation |
| Last Change Date | 25-Nov-2014 |

donepezil (transdermal patch, Alzheimers disease), Corium DEVELOPMENT PROFILE

SUMMARY

Corium is investigating a transdermal patch formulation of the acetylcholinesterase inhibitor donepezil for the potential treatment of Alzheimer's disease. In November 2014, the company was planning to initiate phase I trials in the first half of 2015.

donepezil (transdermal patch, Alzheimers disease), Corium DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS

| Company | Indication | Country | Development Status | Date |
|--------------------------|--------------------|---------|--------------------|-------------|
| Corium International Inc | Alzheimers disease | US | Discovery | 03-Mar-2014 |

donepezil (transdermal patch, Alzheimers disease), Corium CHEMICAL STRUCTURES

[Return to Table of Contents](#)



| | |
|--|-------------------|
| CAS Registry Number: | Confidence Level: |
| 120014-06-4 | 1 |
|  | |
| Name | Type |
| donepezil | BAN; INN |
| NAL-8817 | Research Code |
| NAL-8812 | Research Code |

donepezil (transdermal patch, Alzheimers disease), Corium DRUG NAMES

| | |
|---|------|
| Names | Type |
| donepezil (transdermal patch, Alzheimers disease), Corium | |

[Return to Table of Contents](#)

aripiprazole (transdermal patch, psychiatric disorder), Aequus Pharmaceuticals/Corium

aripiprazole (transdermal patch, psychiatric disorder), Aequus Pharmaceuticals/Corium SNAPSHOT

| | |
|-----------------------------|---|
| Drug Name | aripiprazole (transdermal patch, psychiatric disorder), Aequus Pharmaceuticals/Corium |
| Key Synonyms | aripiprazole |
| Originator Company | Transdermal Research Pharm Laboratories LLC |
| Active Companies | Aequus Pharmaceuticals Inc;Corium International Inc |
| Inactive Companies | Transdermal Research Pharm Laboratories LLC |
| Highest Status | Discovery |
| Active Indications | Psychiatric disorder |
| Target-based Actions | 5-HT 2a receptor antagonist |
| Other Actions | Dopamine D2 receptor partial agonist;Antipsychotic;5-HT 1a receptor partial agonist |
| Technologies | Patch formulation;Small molecule therapeutic;Transdermal formulation |
| Last Change Date | 24-Nov-2014 |

aripiprazole (transdermal patch, psychiatric disorder), Aequus Pharmaceuticals/Corium DEVELOPMENT PROFILE

SUMMARY

Aequus Pharmaceuticals, (under license from Transdermal Research) in collaboration with Corium is investigating a transdermal formulation of aripiprazole (AQS-1301), a partial dopamine D2 and 5-HT 1A receptor agonist and 5-HT 2A receptor antagonist, for the potential treatment of psychiatric disorders, including schizophrenia, bipolar disorder and, major depressive disorder,. In September 2013, the drug was in preclinical development . In May 2014, the company planned to initiate clinical trials in 2014.


aripiprazole (transdermal patch, psychiatric disorder), Aequus Pharmaceuticals/Corium DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

| Company | Indication | Country | Development Status | Date |
|---|----------------------|---------|--------------------|-------------|
| Aequus Pharmaceuticals Inc | Psychiatric disorder | US | Discovery | 26-Sep-2013 |
| Corium International Inc | Psychiatric disorder | US | Discovery | 27-May-2014 |
| Transdermal Research Pharm Laboratories LLC | Psychiatric disorder | US | Discontinued | 26-Sep-2013 |

aripiprazole (transdermal patch, psychiatric disorder), Aequus Pharmaceuticals/Corium CHEMICAL STRUCTURES

[Return to Table of Contents](#)

| CAS Registry Number: | Confidence Level: |
|--|-------------------|
| 129722-12-9 | 1 |
|  | |
| Name | Type |
| aripiprazole | BANN; INN; USAN |
| Abilify | Trade Name |
| Abilitat | Trade Name |
| Abilify Maintena | Trade Name |
| ALKS-9070 | Research Code |
| OPC-31 | Research Code |
| ZY-102 | Research Code |
| OPC-14597 | Research Code |
| ALKS-9072 | Research Code |
| BMS-337039 | Research Code |


aripiprazole (transdermal patch, psychiatric disorder), Aequus Pharmaceuticals/Corium DRUG NAMES

| Names | Type |
|---|-----------------|
| aripiprazole (transdermal, psychiatric disorder), Aequus Pharmaceuticals/Corium | |
| AQS-1301 | Research Code |
| aripiprazole (transdermal, psychiatric disorder), Transdermal Research | |
| aripiprazole | BANN, INN, USAN |
| aripiprazole (transdermal patch, psychiatric disorder), Aequus Pharmaceuticals/Corium | |

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

| Company Name | Principal | | Partner | | Total |
|---|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Aequus Pharmaceuticals Inc | 1 | 0 | 1 | 0 | 2 |
| Transdermal Research Pharm Laboratories LLC | 1 | 0 | 0 | 0 | 1 |
| Corium International Inc | 0 | 0 | 1 | 0 | 1 |

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

| Deal Type | Active | Inactive | Total |
|--|--------|----------|-------|
| Technology - Other Proprietary | 1 | 0 | 1 |
| Drug - Development/Commercialization License | 1 | 0 | 1 |

[Return to Table of Contents](#)

polio vaccine (transdermal), Corium

polio vaccine (transdermal), Corium SNAPSHOT

| | |
|----------------------|--|
| Drug Name | polio vaccine (transdermal), Corium |
| Key Synonyms | |
| Originator Company | Corium International Inc |
| Active Companies | Corium International Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Poliovirus infection |
| Target-based Actions | |
| Other Actions | Vaccine;Anti-inflammatory |
| Technologies | Patch formulation;Biological therapeutic;Transdermal formulation |
| Last Change Date | 19-Nov-2014 |

polio vaccine (transdermal), Corium DEVELOPMENT PROFILE

SUMMARY

Corium International is investigating a transdermal formulation of polio vaccine using its MicroCor technology, for the potential prevention or treatment of polio.

polio vaccine (transdermal), Corium DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

| Company | Indication | Country | Development Status | Date |
|--------------------------|----------------------|---------|--------------------|-------------|
| Corium International Inc | Poliovirus infection | US | Discovery | 18-Nov-2014 |

polio vaccine (transdermal), Corium DRUG NAMES


| Names | Type |
|-------------------------------------|------|
| polio vaccine (transdermal), Corium | |

[Return to Table of Contents](#)



DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

| Company Name | Principal | | Partner | | Total |
|---------------------------|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Corium International Inc | 1 | 0 | 0 | 0 | 1 |
| World Health Organization | 0 | 0 | 1 | 0 | 1 |

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

| Deal Type | Active | Inactive | Total |
|----------------|--------|----------|-------|
| Drug - Funding | 1 | 0 | 1 |

[Return to Table of Contents](#)

ropinirole + pramipexole (transdermal patch, Parkinsons disease), Corium

ropinirole + pramipexole (transdermal patch, Parkinsons disease), Corium SNAPSHOT

| | |
|----------------------|---|
| Drug Name | ropinirole + pramipexole (transdermal patch, Parkinsons disease), Corium |
| Key Synonyms | |
| Originator Company | Corium International Inc |
| Active Companies | Corium International Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Parkinsons disease |
| Target-based Actions | Dopamine D3 receptor agonist;Dopamine D2 receptor agonist |
| Other Actions | Antiparkinsonian |
| Technologies | Drug combination;Transdermal formulation;Patch formulation;Small molecule therapeutic |
| Last Change Date | 18-Feb-2015 |

ropinirole + pramipexole (transdermal patch, Parkinsons disease), Corium DEVELOPMENT PROFILE

SUMMARY

Corium International is investigating a combination of ropinirole, a dopamine D2 and D3 receptor agonist and pramipexole, a dopamine D3 receptor agonist, as a transdermal patch, for the potential treatment of Parkinsons disease. In September 2014, the combination was in preclinical development and at that time, the company was planning to develop the combination under a 505(b)(2) regulatory pathway.

ropinirole + pramipexole (transdermal patch, Parkinsons disease), Corium DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS


| Company | Indication | Country | Development Status | Date |
|--------------------------|--------------------|---------|--------------------|-------------|
| Corium International Inc | Parkinsons disease | US | Discovery | 30-Sep-2014 |


ropinirole + pramipexole (transdermal patch, Parkinsons disease), Corium CHEMICAL STRUCTURES

[Return to Table of Contents](#)



| | |
|--|-------------------|
| CAS Registry Number: | Confidence Level: |
| | 1 |
|  | |
| Name | Type |
| ropinirole + pramipexole | |

| | |
|--|-------------------|
| CAS Registry Number: | Confidence Level: |
| 104632-26-0 | 1 |
|  | |
| Name | Type |
| pramipexole | BANN; INN; USAN |
| Mirapex ER | Trade Name |
| U-98528E | Research Code |
| SND-919 | Research Code |

| | |
|---|-------------------|
| CAS Registry Number: | Confidence Level: |
| 91374-21-9 | 1 |
|  | |

[Return to Table of Contents](#)

| Name | Type |
|------------|-----------------|
| ropinirole | BANN; INN; USAN |
| Requip XL | Trade Name |
| SKF-101468 | Research Code |
| NP-201 | Research Code |
| JZP-7 | Research Code |

ropinirole + pramipexole (transdermal patch, Parkinsons disease), Corium DRUG NAMES

| Names | Type |
|--|------|
| ropinirole + pramipexole (transdermal patch, Parkinsons disease), Corium | |
| ropinirole + pramipexole | |

[Return to Table of Contents](#)

tamsulosin (transdermal/Corplex, benign prostatic hyperplasia), Corium

tamsulosin (transdermal/Corplex, benign prostatic hyperplasia), Corium SNAPSHOT

| | |
|----------------------|---|
| Drug Name | tamsulosin (transdermal/Corplex, benign prostatic hyperplasia), Corium |
| Key Synonyms | tamsulosin |
| Originator Company | Corium International Inc |
| Active Companies | Corium International Inc |
| Inactive Companies | |
| Highest Status | Suspended |
| Active Indications | Prostate hyperplasia |
| Target-based Actions | Alpha adrenoceptor antagonist |
| Other Actions | |
| Technologies | Transdermal formulation;Patch formulation;Controlled release formulation;Small molecule therapeutic |
| Last Change Date | 16-Feb-2015 |

tamsulosin (transdermal/Corplex, benign prostatic hyperplasia), Corium DEVELOPMENT PROFILE

SUMMARY

Corium International was developing a controlled release transdermal patch formulation of tamsulosin, an FDA-approved urological product as alpha adrenoceptor antagonistic activity, using Corplex transdermal technology, for the potential treatment of benign prostatic hyperplasia,. In November 2013, the drug was listed as being in phase II development, and at that time, the company was seeking to outlicense the drug. However, by September 2014, Corium decided to reallocate capital from the program to its Alzheimer's and Parkinson's disease programs, with any further investment in tamsulosin to be dependent on potential partnering and external funding.

tamsulosin (transdermal/Corplex, benign prostatic hyperplasia), Corium DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS

| Company | Indication | Country | Development Status | Date |
|--------------------------|----------------------|---------|--------------------|-------------|
| Corium International Inc | Prostate hyperplasia | US | Suspended | 30-Sep-2014 |

tamsulosin (transdermal/Corplex, benign prostatic hyperplasia), Corium CHEMICAL STRUCTURES

[Return to Table of Contents](#)



| | |
|--|-------------------|
| CAS Registry Number: | Confidence Level: |
| 106133-20-4 | 1 |
|  | |
| Name | Type |
| tamsulosin | INN |
| GL-2702 | Research Code |
| GLC-2-TA | Research Code |
| NAL-0637 | Research Code |

tamsulosin (transdermal/Corplex, benign prostatic hyperplasia), Corium DRUG NAMES

| Names | Type |
|---|------|
| urological therapeutic (transdermal, benign prostatic hyperplasia), Corium | |
| tamsulosin (transdermal/Corplex, benign prostatic hyperplasia), Corium | |
| tamsulosin | INN |
| alpha adrenoceptor antagonist (transdermal, benign prostatic hyperplasia), Corium | |

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

